Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Following a January announcement of plans for deep R&D cuts, AstraZeneca has revealed which facilities and therapeutic areas will be affected. The company is ending discovery research in thrombosis, acid reflux, ovarian and bladder cancers, systemic scleroderma, schizophrenia, bipolar disorder, depression and anxiety, hepatitis C, and vaccines other than respiratory syncytial virus and influenza. In the U.K., AstraZeneca plans to close its Leicestershire and Cambridge sites, affecting roughly 1,000 researchers, and end pharmaceutical development work at the Avlon facility near Bristol. AstraZeneca will close its Lund, Sweden, site. It will also end discovery research in Wilmington, Del., affecting some 550 scientists.
This article has been sent to the following recipient: